Freeline Therapeutics has announced a new name and brand to reflect its focus on developing a new generation of gene therapies and advancing the practice of genetic medicine. Moving forward, the brand will be called Spur Therapeutics.   Building on compelling data for its lead program FLT201, a highly differentiated gene therapy candidate for Gaucher disease, Spur is pursuing an ambitious research strategy to unlock the promise of gene therapy for more prevalent chronic conditions, starting wi...